Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload.

Summary: Scientists have found a better way to attach powerful cancer-fighting drugs to special proteins called antibodies. These antibodies act like homing missiles to find and stick to cancer cells. By attaching the drug (called DXd) to a very specific spot on the antibody, the medicine becomes much more stable and works better at destroying tumors. This new "site-specific" method could lead to safer and stronger cancer treatments in the future.